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Abstract
Introduction: HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of 
breast cancer with variable prognosis and response to therapy. Although gene expression profiling has identified an 
ERBB2 molecular subtype of breast cancer, it is clear that HER2+ tumors reside in all molecular subtypes and represent 
a genomically and biologically heterogeneous group, needed to be further characterized in large sample sets.
Methods: Genome-wide DNA copy number profiling, using bacterial artificial chromosome (BAC) array comparative 
genomic hybridization (aCGH), and global gene expression profiling were performed on 200 and 87 HER2+ tumors, 
respectively. Genomic Identification of Significant Targets in Cancer (GISTIC) was used to identify significant copy 
number alterations (CNAs) in HER2+ tumors, which were related to a set of 554 non-HER2 amplified (HER2-) breast 
tumors. High-resolution oligonucleotide aCGH was used to delineate the 17q12-q21 region in high detail.
Results: The HER2-amplicon was narrowed to an 85.92 kbp region including the TCAP, PNMT, PERLD1, HER2, C17orf37 
and GRB7 genes, and higher HER2 copy numbers indicated worse prognosis. In 31% of HER2+ tumors the amplicon 
extended to TOP2A, defining a subgroup of HER2+ breast cancer associated with estrogen receptor-positive status and 
with a trend of better survival than HER2+ breast cancers with deleted (18%) or neutral TOP2A (51%). HER2+ tumors 
were clearly distinguished from HER2- tumors by the presence of recurrent high-level amplifications and firestorm 
patterns on chromosome 17q. While there was no significant difference between HER2+ and HER2- tumors regarding 
the incidence of other recurrent high-level amplifications, differences in the co-amplification pattern were observed, as 
shown by the almost mutually exclusive occurrence of 8p12, 11q13 and 20q13 amplification in HER2+ tumors. GISTIC 
analysis identified 117 significant CNAs across all autosomes. Supervised analyses revealed: (1) significant CNAs 
separating HER2+ tumors stratified by clinical variables, and (2) CNAs separating HER2+ from HER2- tumors.
Conclusions: We have performed a comprehensive survey of CNAs in HER2+ breast tumors, pinpointing significant 
genomic alterations including both known and potentially novel therapeutic targets. Our analysis sheds further light 
on the genomically complex and heterogeneous nature of HER2+ tumors in relation to other subgroups of breast 
cancer.
Introduction
Gene amplification is a frequent mechanism of oncogene
activation in breast cancer (BC) [1]. Amplification and
overexpression of the HER2 (HER2/neu, ERBB2) onco-
gene on chromosome 17q12 occur in 15-25% of invasive
BC [2]. HER2-amplified (HER2+) tumors define a clini-
cally important BC subgroup, generally associated with
poor prognosis [2,3]. Strategies to therapeutically target
the HER2 protein by monoclonal antibodies (for example,
trastuzumab) or tyrosine kinase inhibitors (for example,
lapatinib) have been successful [4-7]. As these drugs are
most effective in HER2+ BC, considerable efforts have
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been devoted to accurate assessment of HER2 status, cur-
rently performed by immunohistochemistry (IHC) and/
or in situ hybridization [8]. However, despite the success
of targeted treatment, many HER2+ cases fail to respond
or develop resistance over time.
It is evident that the HER2-amplicon has a variable
structure, comprising other genes in the 17q12-q21
region that may contribute to tumor progression and
treatment effect in HER2+ BC. One of these genes is
topoisomerase IIα (TOP2A), located 700 kb telomeric of
HER2, that may be either co-amplified, unaffected or
deleted in HER2+ tumors [9]. TOP2A status has been
reported to significantly influence the response to anthra-
cycline-based therapy [10-12] although conflicting results
exist [13,14]. Furthermore, it is evident that HER2+
tumors constitute a biologically heterogeneous subgroup
of BC. Global gene expression profiling defines an ERBB2
molecular subtype of BC that predominantly consists of
estrogen receptor (ER) negative HER2+ tumors (HER2+/
ER-) [15,16], while HER2+/ER+ tumors are more hetero-
geneously classified. In addition, we recently used gene
expression profiling to characterize three distinct sub-
groups of HER2+ tumors, and to create a HER2-derived
prognostic gene signature with strong correlation to out-
come for patients with HER2+ disease [17].
Genomic profiling using array comparative genomic
hybridization (aCGH) analysis has revealed frequent
complex copy number alterations (CNAs) on chromo-
some 17q, often including high-level amplifications, in
HER2+ BC [18-20]. Moreover, although HER2+ tumors
share other commonly gained or lost regions with non-
HER2 amplified (HER2-) tumors, the genomic profiles of
HER2+ tumors are more often heterogeneous and com-
plex in nature [18-20]. We designed a study to compre-
hensively investigate CNA patterns in 200 HER2+ tumors
using high-density bacterial artificial chromosome (BAC)
aCGH in concert with custom-designed high-density
zoom-in aCGH [21]. We provide evidence of consider-
able genomic heterogeneity in HER2+ BC, and further
delineate the boundaries of the 17q12-q21 amplicon. In
addition, matched global gene expression profiles were
available for 87 tumors allowing correlation of CNAs to
mRNA expression levels for identification of putative tar-
get genes.
Materials and methods
Patients and tumor material
Freshly frozen HER2+ BC tissue (n = 188) was obtained
from the Southern Sweden Breast Cancer Group's tissue
bank at the Department of Oncology, Lund University
Hospital and from Department of Pathology, Reykjavik
University Hospital. Additionally, 12 formalin-fixed par-
affin embedded (FFPE) tumors were obtained from the
Department of Pathology, Lund University Hospital.
Confirmatory IHC and/or fluorescence in situ hybridiza-
tion (FISH) data were available in 69 of 200 HER2+
tumors [17,22]. Patient and tumor characteristics are
summarized in Table 1 and described in detail in Addi-
tional file 1. The study was approved by the regional Ethi-
cal Committee in Lund (reg. no. LU240-01 and 2009/
658), waiving the requirement for informed consent for
the study, and the Icelandic Data Protection Committee
and the National Bioethics Committee of Iceland. For Ice-
landic patients written informed consent was obtained
according to the national guidelines.
aCGH analysis
BAC microarrays were produced by the SCIBLU Genom-
ics Center [23] in three array formats, 32K (Gene expres-
sion Omnibus, GEO, GPL4723), 33K (GPL7247) and 38K
(GPL9077) all mapped to the UCSC Human Genome
browser build 17 [24]. DNA from fresh frozen and FFPE
tumor tissue was extracted as described (Additional file
2). Array printing, labeling, hybridization, scanning and
image analysis were performed as previously described
[25]. Technical replicate experiments were performed for
15 tumors. Copy number estimates (log2ratios) for each
array were normalized [26] and replicated samples were
merged after normalization. Breakpoint analysis was per-
formed using circular binary segmentation (CBS) with α
= 0.01 [27]. Only segments ≥4 BAC probes were used in
further analyses. Following segmentation, array platforms
were combined into a common array design. CNAs were
detected using sample adaptive thresholds from 250 kb
smoothed data [26] (Additional file 1). Threshold for
amplification was set to segmented log2ratio ≥0.5, and for
high-level amplification to segmented log2ratio ≥1 for
HER2+ tumors. Recurrent high-level amplifications were
defined as single peaks computed from the shortest
region of amplification overlap occurring in >2% of
tumors.  HER2/TOP2A  co-amplification was defined as
segmented log2ratio ≥0.5 for HER2  and  TOP2A. Co-
amplification percentages were calculated as the number
of tumors with co-amplification divided by the lowest
number of the individual amplifications, if not stated oth-
erwise. Pericentromeric BAC probes on the p- and q-arm
of chromosome 17 were identified as the three probes
closest to the chromosome 17 centromer (CEP17) (Addi-
tional file 2). CEP17 amplification was defined as the
average segmented log2ratio ≥0.5 of either the probes on
the p- or q-arm. BAC aCGH data are available through
GEO [28] as [GEO:GSE21259].
Zoom-in aCGH analysis
Custom-designed 60-mer oligonucleotide zoom-in
aCGH arrays with an average probe-to-probe spacing of
100 bp in the 17q12-q21 region were designed using the
Agilent eArray ver. 5.3 software (Agilent Technologies,Staaf et al. Breast Cancer Research 2010, 12:R25
http://breast-cancer-research.com/content/12/3/R25
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Table 1: Patient and tumor characteristics for the 200 HER2+ tumors and the 554 HER2- reference breast cancer data set
HER2+ HER2-*
Number of tumors 200 554
Number of primary tumors 176 --
Number of metastases 5 --
Unknown status 19 --
Tumor size
≤20 mm 57 205
>20 mm 134 226
Mean size mm (SD) 29 (16) 26 (14)
Histological grade
Grade 1 1 41
Grade 2 26 134
Grade 3 38 134
Estrogen receptor status
Positive 76 306
Negative 122 149
Lymph node status
Negative 69 244
Positive 123 194
Age
Median age in years (range) 56 (27 to 84) 55 (28 to 94)
<50 years 77 212
≥50 years 109 252
DNA ploidy status
Aneuploid 112 --
Diploid 39 --
Unknown 49 --
Gene expression subtype**
Basal-like 7 135
ERBB2 51 6
Normal-like 9 35
Luminal A 4 153
Luminal B 10 77
Unclassified 6 42
Overall survival***
Number of deaths 109 190
Within five years 80 107
Median survival in years (range) 7 (0.16 to 18.5) 7.6 (0.1 to 31.9)
Median follow-up in years for patients still 
alive (range)
12.8 (7 to 18.5) 10.2 (1.5 to 20.2)
*: The HER2- data set is composed of four individual data sets as described in Material and methods.
**: Classification in gene expression subtypes according to Hu et al. [41].
***: For primary HER2+ tumors only.Staaf et al. Breast Cancer Research 2010, 12:R25
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Santa Clara, CA) as described (Additional file 2) and per-
formed on 20 tumors (Additional file 1). Microarrays
were processed as described [21]. Breakpoint analysis was
performed using CBS (α = 0.01). Agilent probes were
mapped to the UCSC build 18 [24]. Thresholds for ampli-
fication and high-level amplification were set similarly as
for BAC aCGH data.
Identification of significant copy number alterations and 
fraction of the genome altered
Genomic Identification of Significant Targets in Cancer
(GISTIC) [29] was used to identify significant CNAs in
the 200 tumors (Additional file 2). GISTIC regions with
q-value < 0.25 were identified as significant. Student's t-
test performed on average log2ratios for GISTIC regions
were used to identify regions associated with different
clinical variables, such as ER status, lymph node (LN) sta-
tus, histological grade (grade 3 vs. 1 and 2), DNA ploidy
(diploid vs. aneuploid), tumor size (≤20 mm vs. >20 mm)
and patient age (<50 years vs. ≥50 years) for HER2+
tumors. A false discovery rate-adjusted P-value < 0.05
was considered significant (Additional file 2). Genomic
coordinates for GISTIC regions are mapped to the UCSC
Human Genome browser build 17 [24]. A firestorm-like
amplification pattern [30] was defined as at least three
high-level amplifications larger than three BAC probes
located on the same chromosomal arm, separated by
non-amplified segments, and with a maximum inter-peak
distance <50% of the chromosome arm length. The frac-
tion of the genome altered (FGA) was calculated as previ-
ously described [17].
External aCGH data sets for comparison
CNAs and amplification frequencies in HER2+ tumors
were compared to an assembled HER2- reference BC data
set (n = 554) comprising four BC aCGH data sets, Chin et
al.  [31], Fridlyand et al. [32], Adelaide et al. [33], and
Jönsson et al. (submitted) (Table 1 and Additional file 3).
Data sets were processed individually (Additional file 2),
transformed to a common 100 kb probe set as described
[34], and merged. Clinical follow-up information was
available for the Chin, Fridlyand, and Jönsson data sets.
Gene expression subtype classification [15] was available
for the Chin, Adelaide, and Jönsson data sets (Additional
file 2). Threshold for amplification was set to segmented
log2ratio ≥0.5, and for high-level amplification to seg-
mented log2ratio >0.8 for HER2- tumors in the reference
data set.
Gene expression analysis
Gene expression profiles for 87 HER2+ tumors were
available as either oligonucleotide data (n = 58, Jönsson et
al. submitted) or cDNA data (n = 29) [22] part of larger
BC data sets. Data sets were individually processed and
classified according to different gene signatures (Addi-
tional file 2).
Correlation of gene expression data with genomic 
aberrations
Gene expression data were compared to GISTIC aCGH
log2ratios using Pearson correlation as described [25]. A
correlation cut-off representing P = 0.05 obtained from
10,000 permutations of aCGH sample labels was used to
identify significantly correlated genes in GISTIC regions.
Global correlation analysis using genes mapped to indi-
vidual BAC probes was performed similarly, with two
modifications; segmented log2ratios were used for indi-
vidual BAC probes and 1,000 permutations were per-
formed for P-value estimation.
Survival analysis
Overall survival (OS), univariate and multivariate regres-
sion analyses were performed in R [35] using the Survival
package. Survival curves were compared using Kaplan-
Meier estimates and the log-rank test. The full follow-up
time was used for log-rank tests and regression analyses if
not specified otherwise. In multivariate analysis stratified
tumor size and LN status were included as covariates.
Tick marks in Kaplan-Meier plots indicate censored fol-
low-up.
Results
Extent and patterns of 17q12-q21 amplification in HER2+ 
breast cancer
The 17q12-q21 amplification pattern was analyzed in 200
HER2+ tumors using BAC aCGH. The ability of the BAC
aCGH platform to accurately estimate HER2 copy num-
bers was confirmed by parallel FISH analysis (Additional
file 2) in 13 FFPE HER2-amplified tumors, showing a
good correlation between the techniques (Figure S1A in
Additional file 4). The smallest region of amplification
overlap (SRO) for the HER2  amplicon was 248 kbp
(chr17:34979166-35227087, hg17 build), involving 10
RefSeq genes (Figure 1A). The most frequently up-regu-
lated genes (gene expression log2ratio ≥1) in this SRO
were HER2 (92% of samples) followed by GRB7 (85%),
C17orf37  (79%),  PERLD1  (72%),  PPP1R1B  (63%) and
STARD3 (62%), while gene expression data were unavail-
able for NEUROD2, TCAP, PNMT and ZNFN1A3. The
HER2 SRO was further delineated by zoom-in aCGH to
85.92 kbp (chr17:35074472-35160391, hg18 build)
including TCAP, PNMT, PERLD1, HER2, C17orf37 and
GRB7. Thus, this analysis excluded STARD3, since three
tumors showed an amplicon breakpoint within the gene,
while one tumor had an amplicon starting immediately
telomeric of STARD3 (Figures 1B and 1C).
HER2/TOP2A  co-amplification was observed in 61
tumors (31%) with an SRO of approximately 1,050 kbpStaaf et al. Breast Cancer Research 2010, 12:R25
http://breast-cancer-research.com/content/12/3/R25
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Figure 1 Extent and pattern of the HER2-amplicon on chromosome 17q12-q21 in HER2+ BC. (A) Frequency of amplification across 200 HER2-
amplified tumors analyzed by BAC aCGH. Frequency estimates correspond to number of tumors with segmented log2ratio >0.5 for respective BAC 
probe and are displayed at respective BAC probe's center position (red circles). Shortest region of amplification overlap (SRO) was defined from in-
volved BAC probes genomic start and stop position and is marked with a light gray background. Genomic position of eight BAC probes mapping to 
the SRO is displayed together with their center position (black circle). (B) Close-up of chr17:35000001-35200000 (hg18 build) for tumor TAX577717 
analyzed by zoom-in oligonucleotide aCGH. (C) Close-up of chr17:35000001-35867695 (hg18 build) for tumor TAX577700 analyzed by zoom-in aCGH.
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(chr17:34873000-35921000, hg17 build) using BAC
aCGH, and narrowed to 783.64 kbp (chr17:35067680-
35851322, hg18 build) using zoom-in aCGH (Figure 1C).
TOP2A mRNA levels were significantly higher in HER2/
TOP2A co-amplified cases as compared to non-amplified
HER2+ tumors (P = 3 × 10-5 and 7 × 10-8, respectively for
TOP2A loss and TOP2A normal cases, t-test) in agree-
ment with Arriola et al. [20], as well as compared to
HER2- tumors, classified according to gene expression
subtypes (for example, P = 0.0002 for HER2+/TOP2A+
vs. HER2- basal-like tumors, t-test) (Figure S1B in Addi-
tional file 4). Intriguingly, HER2+/TOP2A+ tumors
showed significantly lower S-phase fractions and lower
correlation to a gene expression grade signature [36] than
HER2+/TOP2A- tumors (P  = 0.004 and 0.001, respec-
tively, t-test) (Figure S1B in Additional file 4). Addition-
ally, HER2/TOP2A co-amplification was associated with
ER+ tumor status, as also observed by others [19,37], as
well as patient age ≥50 years (P = 0.008 and 0.03, respec-
tively, Fisher's exact test), but not to other clinical vari-
ables. Loss of TOP2A  was found in 36 (18%) HER2+
tumors, while the remaining 51% had neither loss nor
amplification of TOP2A. Moreover, none of 554 HER2-
tumors had focal TOP2A amplification.
Extent and patterns of significant CNAs on chromosome 17 
in HER2+ breast cancer
Chromosome 17q has been reported to frequently harbor
complex CNAs in HER2+ BC, often involving other high-
level amplifications together with the 17q12 locus [18-
20]. GISTIC analysis was used to identify and delineate
17 significant regions (10 gains, including the HER2
amplicon, and 7 losses) on chromosome 17 in the 200
HER2+ tumors (Figure 2, Additional file 5). Recurrent
high-level amplifications were observed in 12 of 17
regions, of which amplifications on 17q11.2, 17q12 (cen-
tromeric of HER2), 17q12 (HER2), 17q21.33 and 17q23.2
(centromeric) were more prevalent in HER2+ compared
to HER2- tumors. While 41% of all HER2+ tumors con-
tained ≥1 other recurrent 17q amplicon besides HER2, no
recurrent amplifications were identified on 17p. Several
genes in the 17 GISTIC regions showed significant corre-
lation between mRNA expression and copy number lev-
els, including genes and miRNAs implicated in BC
oncogenesis like RPS6KB1 [38], PPM1D [18] and mir-21
[39] on 17q23.2 (Additional file 5). MYST2, proposed as
the candidate oncogene in the 17q21.33 region [40], was
amplified in 20% of the tumors, however, located centro-
meric of the 17q21.33 GISTIC region. Besides the associ-
ation of amplification on 17q11.2 with ER+ tumor status
(P  = 0.009, Fisher's exact test), none of the other 17q
amplicons were significantly correlated with ER status,
LN status, tumor size, histological grade or patient age,
possibly due to the small sample numbers for individual
amplicons.
Amplification of centromeric regions on chromosome
17 (CEP17 amplification) was observed in 22 (11%)
tumors using the closest pericentromeric BAC probes.
CEP17 amplification based on copy number status for
BAC probes on either 17p11.1 or 17q11.1 was found in 37
(19%) HER2+ tumors. By comparison, only four (1%)
HER2- tumors in the Jönsson et al. data set showed
CEP17 amplification based on either pericentromeric
BAC probes, or average copy number of BAC probes on
either 17p11.1 or 17q11.1. Zoom-in aCGH analysis fur-
ther delineated the pattern of amplification in the centro-
meric region, identifying amplification of a region
including the WSB1  gene (chr17:22558232-22751802,
hg18) as the most frequent in tumors with CEP17 ampli-
fication.
Recurrent amplifications and firestorm-like amplification 
patterns in HER2+ breast cancer
Excluding chromosome 17, recurrent high-level amplifi-
cations were observed with varying frequencies on chro-
mosomes 1, 5, 6, 8, 11, 19 and 20 in 90 (45%) of HER2+
tumors (Additional file 6). Interestingly, there was no sig-
nificant difference in their overall prevalence in HER2+
and HER2- tumors (P > 0.05, Bonferroni adjusted Fisher's
exact test). Identified amplifications included several
known BC amplicons and oncogenes, for example, 8p12
(FGFR1,  LSM1,  RAB11F1P1,  PPAPDC1B), 8q24.21
(MYC), 11q13.3 (CCND1) and 20q13.2 (ZNF217). Co-
occurrence of amplicons was also common as 30%, 9%
and 8% of the 90 tumors had two, three or more than
three recurrent amplifications, respectively. A number of
chromosome regions were frequently co-amplified:
amplifications on 8q (one with another), most regions on
17q (with each other), 1q32.1-q32.2 with 8q24.21, and
20q13.2 with 20q13.32 (Figure 3A). Interestingly, while
high-level amplifications of 8p12, 11q13.3 and 20q13.2
were mutually exclusive in the HER2+ tumors, these co-
amplifications were not uncommon in HER2- tumors
(Figure 3). Furthermore, co-occurrence of high-level
amplifications at 8p12 with 8q24.21, and 20q13.2 with
8q24.21 were also rare in HER2+ tumors compared to
HER2- tumors (Figure 3). High-level amplifications of
other putative oncogenes, for example, PIK3CA, ESR1,
EGFR, KIT, MDM2 and  MYB, were rare in HER2+
tumors (≤1%). Amplifications on 11q13.3, 11q13.5 and
19q13.42 were associated with ER+ tumor status (P  =
0.002, 0.06, 0.03 respectively, Fisher's exact test), corrobo-
rating previously reported association of 11q13.3 to
HER2+/ER+ disease [19]. No recurrent amplification was
associated with LN status, tumor size or patient age.
A firestorm-like amplification pattern (firestorms) has
been defined as multiple closely spaced high-level ampli-Staaf et al. Breast Cancer Research 2010, 12:R25
http://breast-cancer-research.com/content/12/3/R25
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fications limited to single chromosome arms [30]. In
total, 115 firestorms were observed in 88 (44%) HER2+
t u m o r s.  F i r e s t o rm s  o bse rv ed  o n  p - a rm s  ( n  =  1 4 )  w e r e
predominantly located on 1p (36%), 6p (21%) and 12p
(14%), while firestorms observed on q-arms (n = 101)
were predominantly located on 17q (57%), 8q (16%), 20q
(5%), 6q (4%), 12q (3%), and 1q (3%). By comparison, a
total of 39 firestorms were observed in 30 (10%) HER2-
tumors in the Jönsson et al. data set analyzed similarly on
the same BAC aCGH platform. Firestorms in these
HER2- tumors were predominantly located on 1q, 6q, 8q,
11q, 12p, 12q, and 17q (>1 firestorm). Amplification
peaks in observed firestorms were rarely recurrent across
HER2+ tumors, except for a few peaks on 17q that were
o b s e r v e d  i n  m u l t i p l e  t u m o r s .  P r e v a l e n c e  o f  f i r e s t o r m s
was correlated with LN+ status and DNA aneuploidy in
HER2+ tumors (P = 0.02 and 0.009, respectively, Fisher's
exact test), but not to ER status or tumor size.
Figure 2 Extent, frequency and patterns of CNAs on chromosome 17 in HER2+ BC. Regions of loss are shown in green, normal in black, gain in 
dark red, amplification in red, and high-level amplification in white for each sample (row). Frequency of gain (red) and loss (green) across all 200 tumors 
are shown for chromosome 17. Read boxes, above the cytoband bar, indicate GISTIC regions of gain and green boxes GISTIC regions of loss. GISTIC 
regions with recurrent amplifications that are more frequent in HER2+ BC compared to HER2- BC are named. Vertical purple line corresponds to cen-
tromer limit.
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Figure 3 Pattern of co-occurrence of recurrent amplifications in HER2+ and HER2- BC. (A) Fraction of co-amplification of recurrent amplifica-
tions in HER2+ BC excluding the 17q12 HER2 locus. For each amplification (vertical axis), the fraction of samples with a co-amplification (horizontal 
axis) is indicated in each box. Only co-amplifications occurring in ≥2 tumors with fractions ≥0.2 are displayed. For example, 20% of tumors with 17q24.2 
amplification also have 1q21.2 amplification, while 40% of tumors with 1q21.2 amplifications also show amplification at 17q24.2 indicating that the 
number of 1q21.2 amplified tumors is lower than the number of tumors with 17q24.2 amplification. (B) The fraction of co-amplification of recurrent 
amplifications in A in HER2- breast tumors. Only co-amplifications occurring in ≥3 tumors with fractions ≥0.2 are displayed. Fractions are calculated 
similarly as in A.
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Comparison of DNA copy number alterations in HER2+ and 
HER2- breast cancer
HER2+ tumors revealed considerable genomic heteroge-
n e i t y  w i t h  t h e  m o s t  f r e q u e n t  C N A s  ( > 3 0 %  o f  t u m o r s )
being gain on 1q, 5p, 6p, 8q, 9q, 11q, 12p, 12q, 16p, 17q,
19p, 19q, 20p, 20q and 21q, and loss on 1p, 3p, 8p, 9p,
11q, 16q, 17p, 17q and 18q (Figure 4A). GISTIC analysis
identified 117 regions (58 gains, 59 losses), located across
all autosomes including numerous candidate genes and
miRNAs (Figure 4A, Additional file 5).
Several GISTIC regions showed significant differences
in frequency when HER2+ tumors were compared to
HER2- tumors classified into gene expression subtypes
(Table 1, Figure 4B, Additional file 7). Basal-like tumors
were characterized by more frequent losses on 2q37.1, 4p,
4q, 5q, 9q, 10q, 11p15.5 and 14q, and gain of 1p22.1,
3q26.32, 10p13 and 12p13.31 compared to HER2+
tumors. Luminal A tumors were characterized by more
frequent losses on 16q, while other GISTIC regions were
less frequently altered compared to HER2+ tumors.
Luminal B tumors were characterized by more frequent
losses on 6q, 11q, 16q and 22q compared to HER2+
tumors, while normal-like tumors were characterized by
an overall lower CNA frequency.
The average fraction of the genome altered (FGA), rep-
resenting the percentage of BAC clones subjected to gain
or loss for each sample, for HER2+ tumors was 0.34,
equally divided between gains (0.18) and losses (0.16).
HER2+/ER- tumors showed significantly lower FGA than
HER2-/ER- tumors (P = 9 × 10-11, t-test), while HER2+/
ER+ tumors were not different from HER2-/ER+ tumors
(P = 0.11). A similar comparison of HER2+ tumors to
HER2- tumors of various gene expression subtypes
showed significantly higher FGA in basal-like (P < 2 × 10-
16) and luminal B (P = 0.0001) tumors, but lower FGA in
luminal A (P = 0.0003) and normal-like tumors (P = 0.04)
compared to HER2+ tumors.
Differences between HER2+ and basal-like breast cancer
Since most ER- tumors are found in the ERBB2 and basal-
like gene expression subtypes [15,41], we performed sep-
arate comparisons of HER2+/ER- tumors vs. HER2-
basal-like tumors, and ERBB2 classified tumors vs.
HER2- tumors classified according to gene expression
subtypes. Comparison of HER2+/ER- tumors vs. basal-
like tumors resulted in similar findings as for all HER2+
tumors vs. basal-like tumors (Figure 4C). Moreover, com-
parison of ERBB2 classified HER2+ tumors (n = 51) to
basal-like tumors identified similar regions as in the com-
parison of HER2+/ER- tumors (Additional file 8). We
were not able to confirm findings that loss of 15q14-q21
and 9p21.3 separate basal-like tumors from HER2+
tumors [18]. In addition, HER2+ tumors displayed differ-
e n c e s  i n  m R N A  e x p r e s s i o n  o f  t w o  d i f f e r e n t  E R  g e n e
expression modules [42,43] compared to HER2- tumors
classified according to the gene expression subtypes in
the Jönsson et al. data set (Additional file 9). Notably,
basal-like tumors displayed considerably lower expres-
sion of the ER gene expression modules compared to
HER2+/ER- tumors, while the difference between
HER2+/ER- and HER2+/ER+ tumors was less pro-
nounced.
DNA copy number alterations in subgroups of HER2+ 
breast cancer
Highly similar CNA frequencies were observed when
HER2+ tumors were stratified by ER status, with appar-
ent differences being limited to more frequent loss of 1p,
11q and 16q and gain of 11q13 in HER2+/ER+ tumors,
and loss of 5q in HER2+/ER- tumors (Additional file 10).
Supervised analysis of subgroups of HER2+ tumors
defined by clinical or tumor biomarkers identified 11
GISTIC regions significantly associated with ER status or
DNA ploidy (Figure 4D). Several GISTIC regions (for
example, +1p31.3, - 5q14.3, +11q13.3, - 16q23.3) sepa-
rated ER+ from ER- tumors in HER2+ BC, but their effect
was evident also in HER2- tumors (P = 0.06, 5 × 10-23,
0.0002, 0.0003 respectively in HER2- tumors, Bonferroni
adjusted t-test). No GISTIC regions separated HER2+
tumors stratified by patient age, LN status, tumor size, or
histological grade 1 or 2 vs. 3. Differences in FGA were
observed for HER2+ tumors stratified by LN status (P =
0.02, t-test) and DNA ploidy (P = 1 × 10-8), but not by ER
status, tumor size, histological grade or patient age.
Of the 200 HER2+ tumors analyzed by BAC aCGH, 87
had concurrent gene expression data and were classified
according to the gene expression subtypes [15] (Table 1).
Notably, 24% of tumors classified to the ERBB2 subtype
were ER-positive. The individually small subtype groups
prevented individual pair-wise comparisons with the
ERBB2 subtype. However, no significant GISTIC regions,
and no significant difference in FGA were found in a pair-
wise comparison of the tumors in the ERBB2 subtype (n =
51) vs. tumors in remaining expression subtypes com-
bined (n = 30). Strikingly, 83% of HER2+/ER- cases with
available gene expression data were classified into either
the basal-like or ERBB2 subtype, while only 30% of
H E R 2 + / E R +  t u m o r s  w e r e  c l a s s i f i e d  t o  a n y  o f  t h e  t w o
luminal subtypes.
Associations of histopathological and genomic 
characteristics with overall survival
LN status, DNA ploidy and tumor size were independent
significant variables for OS in 176 patients with primary
HER2+ BC, while ER status, patient age and histological
g r a d e  w e r e  n o t  a s s o c i a t e d  w i t h  O S  ( T a b l e  2 ) .  H E R 2 +
cases classified to the ERBB2 gene expression subtype
have been reported to show a tendency for poorerStaaf et al. Breast Cancer Research 2010, 12:R25
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Figure 4 Significant CNAs in HER2+ BC in relation to molecular subtypes. (A) Frequency of gain (red) and loss (green) in 200 HER2+ tumors. Blue 
regions indicate significant CNAs identified by GISTIC analysis. (B) GISTIC regions differing HER2+ tumors from HER2- tumors classified according to 
the molecular subtypes as basal-like, luminal A, luminal B and normal-like (P < 0.05, Bonferroni adjusted Fisher's exact test). Each box represents a GIS-
TIC region, red indicates more frequent gain, and green indicates more frequent loss. (C) GISTIC regions differing HER2+/ER- tumors from HER2- tu-
mors classified as basal-like. Regions identified by Bonferroni adjusted Fisher's exact test (P < 0.05). Each box represents a GISTIC region, red indicates 
more frequent gain, and green indicates more frequent loss. (D) GISTIC regions associated with ER status and DNA ploidy in HER2+ BC. Regions iden-
tified by Student's t-test with FDR-adjusted P < 0.05. Each box represents a GISTIC region, red indicates more frequent gain, and green indicates more 
frequent loss.
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relapse-free survival compared to HER2+ cases classified
to the other subtypes [44]. However, we were not able to
verify such a prognostic association using OS as an end-
point in the current study, for either all five subtypes sep-
arately, or the ERBB2 subtype vs. remaining four subtypes
combined (data not shown).
There was a trend towards a different outcome for
patients stratified according to TOP2A status (Figure 5A),
and stratification by HER2  copy number estimates
showed that patients with the highest HER2 copy number
estimates had significantly worse OS compared to tumors
with the lowest estimates (Figures 5B and 5C). However,
the difference in OS for the latter case is at least partly
explained by that cases in the group with the highest
HER2 copy numbers were more frequently DNA aneu-
ploid (P = 0.1, Fisher's exact test) and displayed higher
FGA values (P = 0.04, t-test) compared to cases in the
group with the lowest copy numbers. No association with
outcome was seen for the presence of recurrent amplifi-
cations or firestorms in patients with primary HER2+ BC.
This lack of association remained significant also when
stratifying patients with DNA aneuploid or diploid
HER2+ tumors for presence of recurrent amplifications
or firestorms respectively (data not shown). In contrast,
patients with HER2- tumors displaying a firestorm-like
amplification pattern in the Jönsson et al. data showed
significantly worse OS (log-rank P = 0.0008) supported by
multivariate analysis (n = 250, P = 0.002, HR = 2.3, 95%
confidence interval (CI) = 1.4 to 3.8). A tendency for
worse OS was observed for HER2+ cases with high vs.
low FGA (log-rank P = 0.08) especially for HER2+/ER+
tumors (Table 2). The association was however weakened
considerably when FGA was stratified for DNA aneu-
ploidy (log-rank P = 0.52 for all tumors and P = 0.65 for
HER2+/ER+ tumors), while DNA aneuploidy still added
prognostic information when stratified for FGA (log-rank
P = 0.02 for all tumors, P = 0.07 for HER2+/ER+ tumors).
Low sample numbers hampered the investigation of indi-
vidual recurrent amplifications, but 10 GISTIC regions
showed moderate association to OS (log-rank P < 0.1)
when comparing gain or loss vs. normal copy number in
HER2+ cases (Figure 5D). Three of these regions (-3p.13,
+5q35.2 and +8p12) were also associated with OS in the
combined HER2- reference data set (log-rank P = 0.004,
Table 2: Log-rank, univariate and multivariate associations with OS for clinical variables and genomic characteristics for 
176 primary HER2+ tumors
Investigated covariatea Number 
tumors
Log-rank
P
Univariate
P
Multivariate
Pb
ER+ vs. ER- 64/112 0.96 0.96 0.79
LN+ vs. LN- 110/65 4 × 10-6 *** 9 × 10-6 *** 0.0002***
Size >20 mm vs. ≤ 20 mm 122/49 0.002** 0.002** 0.02*
Histological grade 3 vs. 1 and 2 37/26 0.91 0.91 0.83
Age <50 vs. ≥50 years 73/103 0.22 0.23 0.77
DNA Aneuploid vs. Diploid 106/37 0.001** 0.001** 0.005**
DNA Aneuploid vs. Diploid ER+ 37/11 0.008** 0.02* 0.07
DNA Aneuploid vs. Diploid ER- 69/26 0.05* 0.05* 0.06
Recurrent 17q amplification, yes 
vs. no
70/106 0.17 0.17 0.13
Recurrent amplification 
excluding 17q, yes vs. no
76/100 0.75 0.75 0.7
Firestorm pattern, yes vs. no 78/98 0.27 0.28 0.58
High FGA vs. low FGAc 42/46 0.08 0.09 0.25
High FGA vs. low FGA ER+ 
tumorsc
18/17 0.09 0.09 0.26
High FGA vs. low FGA ER- 
tumorsc
24/29 0.37 0.37 0.55
a Variables with worst outcome highlighted in bold for covariates significantly associated with OS.b Multivariate analysis included LN status 
and stratified tumor size besides the tested covariate.c High and Low FGA defined as >75th percentile and <25th percentile of all FGA values 
respectively.
*: Significant at P < 0.05
**: Significant at P < 0.01
***: Significant at P < 0.001Staaf et al. Breast Cancer Research 2010, 12:R25
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0.002 and 0.003, respectively) adding either independent
or near independent prognostic information in multivari-
ate analysis (P = 0.08, 0.007 and 0.06, respectively) (Figure
5E). Of these regions, 8p12 has previously been identified
as an indicator of poor breast cancer prognosis [31]. The
association with outcome for the 5q35.2 GISTIC region
was stronger for HER2-/ER- tumors compared to HER2-/
ER+ tumors (log-rank P = 0.006 and 0.07 respectively).
Correlation of gene expression data with genomic 
aberrations
Gene expression data were compared with genomic aber-
rations in 87 HER2+ tumors in order to identify genes
affected by gene dosage. First, genes in the 117 GISTIC
regions (n = 1,750) were matched to available gene
expression data (n = 1,078) and correlated across tumor
samples as previously described [25]. This approach iden-
tified 460 significantly correlated genes, 284 and 176 in
GISTIC regions of gain and loss, respectively (Additional
file 5). Second, analysis was re-performed without the
restriction to genes in GISTIC regions. Of 10,162
matched genes, 5,853 genes (58%) showed a standard
deviation >0.5 in mRNA expression, and 2,242 (38%) of
these genes showed significant correlation between
expression and copy numbers (P < 0.05 adjusted for mul-
tiple testing) (Additional file 11). In summary, correlation
of mRNA and copy number identified numerous breast
cancer tumor suppressor genes and oncogenes, such as
STAT5A,  SNIP,  ZNF217,  TOP2A,  BCL2, PAK1,  PER3,
CCND1, NME1, PPAPDC1B, LSM1, IL17RB and FGFR1,
to be significantly correlated in HER2+ tumors. In addi-
tion, genes previously reported to be significantly corre-
lated in HER2+/TOP2A co-amplified cases (for example,
Figure 5 Association of OS with TOP2A-status, HER2 copy number levels, and GISTIC regions in HER2+ and HER2- tumors. (A) OS in primary 
HER2+ tumors stratified by TOP2A-status. (B) OS in primary HER2+ tumors stratified by the 25th (HER2+ CN low) and 75th percentile (HER2+ CN high) 
of the mean HER2 segmented log2ratio. (C) OS in primary HER2+ tumors stratified by the 15th (HER2+ CN low) and 85th percentile (HER2+ CN high) of 
the mean HER2 log2ratio. (D) GISTIC regions showing association with OS (log-rank P < 0.1) in the 176 primary HER2+ tumors. The vertical axis repre-
sents -log10(p) for log-rank, univariate and multivariate analysis. Tumor size and LN status were included as covariates in multivariate analyses beside 
GISTIC regions. Dashed lines indicate P = 0.1, 0.05 and 0.01. GISTIC regions are ordered according to their genomic position. (E) Association to OS for 
GISTIC regions in D in HER2- tumors. The vertical axis represents -log10(p) for log-rank, univariate and multivariate analysis. Tumor size and LN status 
were included as covariates in multivariate analyses besides GISTIC regions. Dashed lines indicate P = 0.1, 0.05 and 0.01. GISTIC regions are ordered 
according to their genomic position.
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CASC3,  CDC6,  RARA  and  SMARCE1) [20] were also
identified in this study (Additional file 11).
Discussion
We have characterized a large set of HER2+ BC in com-
parison to HER2- BC using a combination of molecular
techniques to delineate the HER2-amplicon in high-
detail, and to pinpoint, on a genome-wide scale, critical
regions of focal amplifications, gains and losses that may
be important for tumor development and reflect the het-
erogeneity of HER2+ BC.
The HER2-amplicon
By using a custom-designed zoom-in aCGH platform we
delineated the shortest region of overlapping amplifica-
tion for the HER2-amplicon to an 85.92 kbp region
including six genes. The identified region is considerably
smaller than previously reported [19,20,45], mainly due
to the larger number of tumors and the extreme probe
density provided by the zoom-in aCGH platform. While
the role of some amplicon genes may be less relevant for
breast cancer development, the function of GRB7  is
intriguing.  GRB7  showed strong correlation between
mRNA transcript levels and copy number status in this
study, and increased mRNA expression has been shown
to correlate with protein overexpression in breast cancer
cell lines [46,47]. As an SH2-containing adapter protein
GRB7 can interact with phosphorylated HER2 and medi-
ate aspects of cell migration through binding with focal
adhesion kinase [48,49]. Furthermore, GRB7  has been
pinpointed as one of the top-ranked genes in a HER2-
derived prognostic gene signature [17], arguing that it is
not merely a silent passenger of the amplicon. However,
we found no case of focal GRB7 amplification in HER2-
cases suggesting that its activation is linked to the
selected advantage conferred by HER2 activation.
CEP17 amplification in HER2+ breast cancer
Accurate evaluation of HER2 status is important for iden-
tification of patients that would benefit from HER2 tar-
geted therapy. FISH analysis for determination of the
ratio of HER2  copy number to chromosomes 17 copy
number, represented by a centromeric chromosome 17
FISH probe (HER2/CEP17 ratio), has been suggested as
the current golden standard [50-52]. However, concerns
h a v e  b e e n  r a i s e d ,  b a s e d  o n  a C G H  a n d  M L P A  s t u d i e s,
whether CEP17 copy number status accurately reflects
true chromosome 17 copy number and polysomy (≥3
copies of the entire chromosome 17) [53-55]. We found
that polysomic chromosome 17, using the definition sug-
gested by Marchio et al. [53], was a rare event in HER2+
breast tumors (1.5% of tumors). While CEP17 amplifica-
tion was a rare event in HER2- tumors, it was observed in
a much higher frequency in HER2+ tumors, consistent
with recent reports [14]. Thus, our data support the
notion that abnormal CEP17 copy numbers more likely
stem from CNAs on chromosome 17q, and that CEP17
correction may for certain cases be misleading for inter-
pretation of HER2 status [53,54].
TOP2A aberrations in HER2+ breast cancer
The variable structure of the HER2 amplicon frequently
involves additional genes telomeric of HER2 [20,56], for
instance TOP2A encoding a protein target of anthracy-
clines [57]. It has become increasingly evident that
TOP2A alterations rarely occur in HER2- breast tumors
(reviewed in [9]) in line with our finding that no HER2-
tumor showed focal amplification of TOP2A. In this
study, TOP2A amplification or deletion was observed in
31% and 18% of HER2+ tumors, respectively, concordant
with previous reports (reviewed in [9]). Consistent with
previous reports [56], we found in tumors analyzed by
high-resolution zoom-in aCGH that co-amplification of
HER2 and TOP2A was not separated by chromosomal
regions with normal or deleted copy numbers, and that
discordance between HER2 and TOP2A copy numbers
existed in co-amplified cases. The strong correlation
between TOP2A copy number and expression level (Fig-
ure S1B in Additional file 4, Additional file 11) and the
abrupt breaks in the HER2/TOP2A amplicon telomeric of
TOP2A in several tumors (for example, Figure 1C), sug-
gest a selective retention of TOP2A  activation in the
development of some tumors through, for instance,
breakage-fusion-bridge cycles [56]. TOP2A  alterations
clearly have a potential role in tumor progression and
treatment response, and have been linked to better dis-
ease-free survival for patients with HER2+ disease
treated with anthracyclines [11,37]. However, TOP2A
protein expression has been reported to correlate more
with cellular proliferation than gene amplification [58], in
line with our findings of elevated TOP2A mRNA levels in
highly proliferative HER2- basal-like and luminal B
tumors for which no focal TOP2A  amplification was
observed (Figure S1B in Additional file 4). Moreover, it
has recently been suggested that alterations in the centro-
meric region of chromosome 17 is a more powerful pre-
dictor of response to anthracycline-based treatment than
alterations in either HER2  or  TOP2A  [14]. Taken
together, the finding of a trend of better OS for HER2+/
TOP2A+ tumors in the present study is difficult to inter-
pret, as we had no specific treatment information avail-
a b l e  f o r  p a t i e n t s  i n  t h i s  s t u d y .  C l e a r l y ,  t h e  c o m p l e x
relationship of individual genes in the 17q12-q21 region,
as well as other genomic alterations on chromosome 17q,
to breast cancer development and treatment efficacy war-
rants further investigation.Staaf et al. Breast Cancer Research 2010, 12:R25
http://breast-cancer-research.com/content/12/3/R25
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Recurrent amplifications and firestorm patterns in HER2+ 
breast cancer
Recurrent high-level amplifications and firestorms were
frequent in HER2+ breast tumors as also observed by
others [18-20]. In line with previous reports, HER2+
t u m o r s  w e r e  f i r m l y  a s s o c i a t e d  w i t h  a n  a m p l i f i e r /
firestorm-like genomic pattern, as firestorms or recurrent
amplifications, excluding the HER2-amplicon, were
observed in 70% of all HER2+ tumors [18,30,31]. How-
ever, only a few recurrent amplifications on chromosome
17q were more common in HER2+ than in HER2-
tumors. In contrast to recent reports [30,31], presence of
firestorms or recurrent high-level amplifications were not
associated with clinical outcome for patients with HER2+
breast tumors. Instead, DNA aneuploidy was a stronger
indicator of poor prognosis, especially for HER2+/ER-
positive tumors, in line with previous reports for breast
cancer irrespective of HER2 status [59,60]. Although
firestorms were significantly more frequent in DNA ane-
uploid HER2+ tumors, 25% of DNA diploid HER2+ cases
displayed firestorms suggesting that occurrence of gross
chromosomal alterations and amplifier patterns may be
unrelated mechanisms of genomic instability.
The majority of identified recurrent amplifications in
this study have previously been reported in both HER2+
and HER2- breast tumors, although with different fre-
quencies and co-amplification patterns [18,31,32,38]. A
few discrepancies exist in comparison to recent aCGH
studies on HER2+ tumors, for example, we did not
observe recurrent (>2%) high-level amplifications on
chromosome 7p, 14q and 18q [18,20]. Interestingly, while
combinations of high-level amplifications of 8p12,
11q13.3 and 20q13.2 were not uncommon in HER2-
tumors, they were mutually exclusive in HER2+ tumors.
When the threshold for high-level amplification was low-
e r e d  t o  t h a t  o f  a m p l i f i c a t i o n ,  c o - o c c u r r e n c e  o f  t h e s e
regions was still rare in HER2+ tumors compared to
HER2- tumors (data not shown). Individual amplification
of 8p12, 11q13.3, or 20q13.2 was associated with worse
OS in HER2- tumors (log-rank P  ≤ 0.02), but not in
HER2+ tumors. Furthermore, co-amplification of
11q13.3 with 8p12 and 11q13.3 with 20q13.2 remained
significantly associated with outcome in HER2- tumors
despite fewer cases, while co-amplification of 8p12 with
20q13.2 showed only a trend (log-rank P = 0.10). Presum-
ably, these amplifications activate cellular pathways that
drive tumor progression synergistically in HER2- tumors,
whereas having more than one of these amplifications
provides no advantage in HER2+ tumors.
Significant CNAs in HER2+ breast cancer
The molecular subtypes of breast cancer [15] have been
associated with distinct CNAs and genomic patterns
[18,31,38,61] that may contribute to their transcriptional
profiles and biological phenotypes [62]. The overall pat-
tern of CNAs in HER2+ breast tumors observed in this
study corroborates earlier findings [18,19]. However, a
few discordances exist, mainly corresponding to more
frequent gain of 16p and less frequent aberrations on
chromosome 7 in the current study. Comparison of
CNAs in HER2+ tumors to HER2- tumors revealed dif-
ferences in FGA and frequency of several GISTIC regions
(Figure 4, Additional files 5, 7, 8). On the other hand,
some of the most recurrent CNAs in HER2+ tumors irre-
spective of ER status, including +1q, +8q, -8p, and -17p,
were also commonly observed in HER2- tumors indicat-
ing their importance in breast cancer. Several of the
regions discriminating HER2+ from HER2- tumors have
previously been reported as specific for basal-like, lumi-
nal A and B tumors respectively [31-33,40,61,63,64].
However, certain discriminatory regions are explained by
the ER status of the 200 HER2+ tumors and the gene
expression subtypes. For instance, HER2- luminal A and
B tumors displayed more frequent loss of 16q than
HER2+ tumors as a whole (Figure 4B). However, when
HER2+/ER+ tumors were compared to luminal A and B
tumors, loss of 16q was no longer significant, reflecting
the strong association of specific CNAs with ER status
(data not shown). Furthermore, our data, supported by
subtype classifications of independent breast cancer data
sets, indicate that the ERBB2 subgroup, although domi-
nated by HER2+/ER- tumors, contains a sizeable fraction
of HER2+/ER+ tumors.
The finding of GISTIC regions stratifying both HER2+
and HER2- tumors based on ER status is in contrast to a
recent smaller aCGH study on HER2+ breast tumors [19].
Interestingly, although HER2+/ER- tumors harbor a pat-
tern of CNAs similar to HER2-/ER- and basal-like
tumors, the frequencies of these aberrations are signifi-
cantly lower in HER2+/ER- tumors as well as ERBB2 sub-
type classified HER2+ tumors, in agreement with
Marchio et al. [19] (Figure 4C, Additional files 5 and 8).
HER2+/ER- tumors have been linked by gene expression
analysis to an apocrine/steroid response-positive sub-
group of ER-negative BC characterized by overexpression
of genes related to steroid estrogen response [65,66].
Moreover, there is increasing support for crosstalk
between the HER2 and ER-signaling pathways (reviewed
by [67,68]). Consistent with these observations and
recent reports [42,69], HER2+ tumors in the current
study showed intermediate expression of two ER gene
expression modules, which were significantly less
expressed in HER2- basal-like tumors. Further substanti-
ating the difference between HER2+/ER- and HER2-
basal-like tumors we did not find elevated frequencies of
CNAs characteristic of HER2- basal-like BC in HER2+
tumors with high correlation to the basal-like gene
expression centroid (data not shown).Staaf et al. Breast Cancer Research 2010, 12:R25
http://breast-cancer-research.com/content/12/3/R25
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In summary, HER2+ tumors display a wide range of fre-
quently complex CNAs including firestorms and recur-
rent amplifications. However, with the exception of a
limited number of CNAs primarily located on chromo-
some 17q, the vast majority of CNAs does not a ppear
specifically associated with HER2+ tumors per se, as
r e v e a l e d  w h e n  c o m p a r e d  t o  o t h e r  b r e a s t  c a n c e r  s u b -
groups. These findings underline the genomically com-
plex and heterogeneous nature of HER2+ breast cancer in
relation to other subgroups of breast cancer.
Conclusions
We have conducted a comprehensive survey of copy
number alterations in HER2+ breast tumors using a com-
bination of aCGH and gene expression analysis, pinpoint-
ing significant genomic alterations including both known
and potentially novel therapeutic targets. Our analysis
sheds further light on the genetically complex and het-
erogeneous nature of HER2+ tumors in relation to other
breast cancer subgroups.
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